Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy

Description

This clinical imaging substudy will use the small molecule translocator protein (TSPO) ligand, Fludeoxyglucose(18F)-labeled DPA-714, to compare neuroinflammation in individuals with high or low grade asymptomatic carotid artery stenosis (aCAD) who are participating in the separate Neuroinflammation in Asymptomatic Carotid Artery Disease study lead by Dr. Ron Lazar (IRB-300007806). The positron emission tomography (PET) tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation.

Conditions

Critical Asymptomatic Carotid Artery Disease, Non-Critical Asymptomatic Carotid Artery Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

This clinical imaging substudy will use the small molecule translocator protein (TSPO) ligand, Fludeoxyglucose(18F)-labeled DPA-714, to compare neuroinflammation in individuals with high or low grade asymptomatic carotid artery stenosis (aCAD) who are participating in the separate Neuroinflammation in Asymptomatic Carotid Artery Disease study lead by Dr. Ron Lazar (IRB-300007806). The positron emission tomography (PET) tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation.

Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy

Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy

Condition
Critical Asymptomatic Carotid Artery Disease
Intervention / Treatment

-

Contacts and Locations

Birmingham

UAB, Birmingham, Alabama, United States, 35294

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Contraindication to MRI
  • 2. Pregnancy or lactation
  • 3. Previous revascularization for treatment of aCAD
  • 4. Prior stroke
  • 5. Severe anemia (blood hemoglobin ≤ 8 mg/dL)
  • 6. Previously obtained MRI scan with evidence of clinically significant abnormality
  • 7. History of traumatic head injury defined by loss of consciousness \>30 minutes or seizure at the time of the injury
  • 8. Major depression
  • 9. Known history of dementia
  • 10. Serious medical comorbidity that, based on the judgement of the principal investigator, may interfere with study participation
  • 11. Low or mixed-affinity binding for TSPO ligands based on genotyping for SNP rs6971.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Alabama at Birmingham,

Jonathan McConathy, MD,PhD, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham

Study Record Dates

2026-12-31